Abstract: Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are two homologous transcriptional coactivators and the final effectors of the Hippo signaling transduction pathway. The transcriptional activity of YAP/TAZ is dependent on their recruitment to the nucleus, which promotes binding to the transcription factor of TEA domain family members 1-4 (TEAD1-4). In Hippo-signaling pathway, YAP/TAZ is inactivated and its translocation to the nucleus is blocked via a core kinase cascade stimulated by a variety of upstream signals, such as G-protein-coupled receptor signaling, mechanical pressure, and adherens junction signaling. This pathway plays a very important role in regulating organ size, tissue homeostasis, and tumor development. In recent years, many studies have reported upregulation or nuclear localization of YAP/TAZ in a number of human malignancies, such as breast cancer, melanoma, lung cancer, especially squamous cell carcinoma in different organs. A large number of experiments demonstrate that YAP/TAZ activation promotes cancer formation, progression, and metastasis. Therefore, in this review, we summarize the evidence of regulation and function of YAP/TAZ and discuss its role in squamous cell carcinoma. Collectively, this summary strongly suggests that targeting aberrant YAP/TAZ activation is a promising strategy for the suppression of squamous cell carcinoma.
Introduction
The Hippo pathway was first discovered in Drosophila during the 1990s. This signal pathway is highly conserved. It regulates organ size and maintains homeostasis during cell proliferation and apoptosis. 1, 2 As the major downstream effectors of the Hippo pathway, YAP and its paralog TAZ 3 are negatively regulated by the Hippo pathway, owing to their phosphorylation 2 and their inability to enter the nucleus. 4 Over the past two decades, a number of studies uncovered four proteins including Wart (Wts), 5 scaffold protein Salvador (Sav), 6, 7 Hippo (Hpo), 1, [8] [9] [10] and Mats, 11 as the central part of the Drosophila Hippo pathway. Based on this, Yorkie (Yki), a transcriptional coactivator acting as a Wts-binding partner, was discovered in 2005. 2 In Drosophila, the YAP's paralog was identified in 2000 as a protein that binds with 14-3-3 protein. 3 Since the discovery of YAP/TAZ, they have emerged as the critical regulators of early embryonic development and adult organs by driving the transcription of genes that promote cell proliferation, cell survival, and stem cell maintenance. 16, 17 Therefore, low activity of YAP/TAZ can lead to developmental defects, defective repair, and organ atrophy. On the contrary, aberrantly high activity of YAP/TAZ promotes cell overgrowth and tumor formation. In this review, we will provide an overview of the Hippo pathway network, the functions of YAP/TAZ, and its regulation. We will also discuss the roles of YAP/TAZ on squamous cell carcinoma.
The Hippo pathway in mammals
Similar to the Drosophila Hippo pathway, the mammalian Hippo pathway is also considered as a tumor suppressor pathway, regulated by a phosphorylation-dependent protein kinase cascade. In Drosophila, the kinase cascade mainly includes mammalian STE20-like protein kinase (MST1/2), large tumor suppressor 1/2 (LATS1/2), human Salvador homology1 (SAV1), and MOB kinase activator (MOB), which are homologous to Hpo, Wts, Sav, and Mats, respectively. 1 The kinase chain can control the activity of the downstream effecter YAP/TAZ ( Figure 1 ).
Activated MST1/2 binds to the regulatory protein SAV1, which promotes the phosphorylation of LATS1/2 and MOB, and subsequently, phosphorylation of YAP/TAZ at serine residue-127. 18, 19 This phosphorylation-dependent process leads to the cytoplasmic retention of YAP/ TAZvia 14-3-3 protein interaction, 7, [20] [21] [22] [23] [24] [25] and its ubiquitination and degradation ( Figure 1 ). 26 Upon inactivation of the Hippo pathway, dephosphorylated YAP/TAZ translocates to the nucleus and binds to the transcription factor TEAD to induce expression of the genes involved in cell proliferation, anti-apoptosis, and epithelial-mesenchymal cell transformation (Figure 1 ). The Hippo pathway observed in mammals is mainly regulated by multiple upstream signal input factors, such as WW, C2 domain-containing protein 1 (KIBRA/WWC1), neurofibromin2 (Nf2), and FERM domain-containing protein 6 (willin/FRMD6). 37 Recently, G protein-coupled receptor (GPCR) signaling was found to act as an upstream signal of the Hippo pathway. It was shown that stimulation of G12/ 13-coupled receptors or Gs-coupled receptors could inhibit or activate Lats1/2, thereby activating or inhibiting YAP/ TAZ to influence cell proliferation and migration. 38 
YAP/TAZ and its regulation
The structure of YAP/TAZ YAP is a transcriptional coactivator of the Hippo pathway and promotes gene expression by enhancing the activity of transcription factors. It has two subtypes, YAP1 and YAP2. YAP contains multiple domains and specific amino acid sequences, including a TEAD-binding region (formed by the 94th serine,S94), two WW domains (consist of amino acids 172-204 and 231-263), an N-terminal proline-rich domain, a C-terminal PDZ-binding motif, an SH3-binding motif, a coiled-coil domain and a transcription activation domain ( Figure 2 ). TAZ is homologous to YAP and has similar domains and functions as YAP. 3 However, it lacks a proline-rich domain, a second WW domain and an SH3-binding motif ( Figure 2) . A previous study demonstrated that the WW domain specifically recognizes the PpxY (P is proline, x is any amino acid and y is tyrosine) motifs, thereby controlling the localization and activity of YAP/TAZ. 39 The C-terminal of YAP/ TAZ can accurately identify the PDZ domain, which is composed of 80-90 amino acids and is present in many proteins. 40 The effect of YAP/TAZ on cell proliferation and apoptosis
Previous studies have suggested that YAP/TAZ is an oncoprotein resulting in cell proliferation. In Drosophila, overexpression of yki (YAP homologue in Drosophila) leads to overgrowth of the third instar wing discs. 2 Researchers have established that mice that overexpresses YAP had a higher mitogenic activity in keratinocytes and thicker basal layer, superstratum, and stratum corneum present on the epidermis than those in wild type mice. On the contrary, mutant YAP gene knockout mice showed marked epidermis shrinkage and delayed wound healing. 41 When the skin was wounded, YAP protein level in the keratinocyte increased and subsequently induced cell proliferation. 41 Another study showed that the proliferation was inhibited in lung cancer cell line A549 transfected with MST1 gene, which was due to high level of YAP phosphorylation. 42 It was also observed that in liver injury caused by cholestasis, high expression of YAP promoted the proliferation of hepatocytes and bile duct epithelial cells, and resulted in the lesser of liver damage. 43 Conditional knockout of YAP/TAZ gene leads to inhibition of hepatocyte regeneration and liver necrosis. 43 Interestingly, high concentrations of bile acid can act as upstream activators of the Hippo pathway, activate YAP transcriptional activity, and stimulate hepatocyte proliferation and tumorigenesis. On the contrary, YAP/TAZ has an inhibitory effect on apoptosis. In Drosophila, Yki protein inhibits cell apoptosis by reducing the activity of apoptosis-related gene reaper (rpr), the binding of P53 with the apoptosis-stimulating protein of P53-1 (ASPP1), and activation of head involution defective (hid). 45 A previous study also confirmed the anti- Barry et al found that YAP restricted nuclear translocation of disheveled (DVL) and the regeneration of intestinal cells. 47 This inhibition was caused by DVL-mediated inactivation of the Wnt signaling pathway. 47 In a study based on tumorigenesis and development, it was found that Smad3/YAP/TEAD/p300 could form complexes to increase the expression of CTGF, promote proliferation of malignant stromal cells, and secretion of extracellular matrix. 48 YAP/TAZ can also interact with the Notch signaling pathway to regulate intestinal homeostasis. Under normal conditions, only Hes-1, a target gene of the Notch signaling pathway, was expressed in the intestinal crypts. 49 Activation of YAP and the expression of Hes-1 was widened and distributed in all chorio-epithelium, which suggested that YAP-mediated expansion of intestinal progenitor cells was at least partially dependent on the activation of the Notch signal. 49, 50 PI3K/AKT pathway can cooperate with the Hippo/YAP signaling pathway to regulate cell proliferation and programmed cell death. 51 It was reported that Pik3cb, one of the genes encoding PI3k, could be directly activated by YAP/TAZ through TEAD to promote PI3K transcription and AKT activation. 52 This mechanism has also been confirmed in rat cardiomyocytes as YAP-mediated PI3K/AKT activation promotes its proliferation and reduces programed cell death. 52 The roles of YAP/TAZ in squamous cell carcinoma
As a downstream function of the Hippo pathway, YAP/TAZ can induce the activation of target genes related to cancer cell proliferation, invasion, and metastasis. Therefore, YAP/TAZ plays an oncogene role in a number of malignant tumors, such as lung, 53 liver, 54 gynecological, 55, 56 gastrointestinal,-57,58 and skin malignant tumors. 59 Among skin malignancies, squamous cell carcinoma (SCC), basal cell carcinoma (BBC), and melanoma are the most common forms. Studies show that in both human and mice BBC, YAP and TAZ were nuclear and highly expressed. 59, 60 Meanwhile, the conditional deletion of YAP and TAZ in mouse models of BCC prevented tumor formation. 59 YAP signaling also accelerated BBC development via the c-JUN/AP1 axis, 60 the positive regulatory interactions with Hedgehog/GLI2 signaling, 61 and its downstream of cysteine-rich protein 61 (CCN1) and connective tissue growth factor (CCN2). 62 For melanoma, recent papers described high expression of TAZ/YAP promoted its progression associated with stimulation of low-density lipoprotein receptor-related protein 1 (LRP1) and affects the postoperative survival of patients. 63, 64 Emerging evidence also suggested that YAP directly mediated evasion of cytotoxic T-cell immune responses in BRAFi-resistant melanoma cells by upregulating PD-L1, and targeting of YAP-mediated immune evasion may improve prognosis of melanoma patients. 65 More and more evidences show that squamous cell carcinoma (SCC) that occurs in different organs covered with squamous epithelium not only restrict to skin, was initiated and determined by YAP/TAZ. Here, we will focus on SCCs and summarize the effect of YAP/TAZ on tumorigenesis and progression of several common SCCs.
Cutaneous squamous cell carcinoma
The homozygous mouse mutant of the gene encoding 14-3-3σ displays severe skin defects such as thick epidermis, high proliferation of basal and spinous layers, and lack of granular and stratum corneum, accompanied with enhanced YAP nuclear localization in epidermal cells. 66 This study demonstrated that YAP/TAZ as a downstream molecule of 14-3-3σ, blocked its binding with1 4-3-3 isoforms and failed to sequester in the cytoplasm due to the mutant, 14-3-3σ. 66 Accumulation of YAP/TAZ in the nucleus causes continued progenitor expansion, inhibition of differentiation in the epidermis, and formation of cutaneous squamous cell carcinoma (CSCC). 66 It was observed that YAP/TAZ is highly expressed in both mouse and human CSCCs and shows elevated expression in wounded skin. 67 When YAP/TAZ was knocked out, proliferation of cells as marked by positive of Ki67 is reduced. 
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AKT and ERK pathways. 68 The two latter pathways are involved in the regulation of cell growth, survival, and migration on CSCC. 68 The S100A7 protein is highly expressed in psoriasis, differentiated SCC, and keratoacanthoma lesions. 69 In the SCC cell line A431, YAP can inhibit the expression of S100A7 protein by binding to TEAD1. Although YAP has lesser protein expression compared to S100A7, researchers believe that both the proteins can promote cell proliferation and inhibit cell differentiation. Moreover, S100A7 protein may be a substitute for YAP to maintain cell survival.
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Esophageal squamous cell carcinoma
Esophageal cancer is one of the most common gastrointestinal cancers. 71 The pathological type of esophageal cancer is mainly esophageal squamous cell carcinoma (ESCC). 72 Muramatsu et al found that the effect of YAP in ESCC depended on its expression level and depletion of YAP inhibited cell proliferation, which was accompanied with an increase in the transcription of CDKN1A/p21, and a decrease in the transcription of BIRC5/survivin. 73 Clinical observation showed that nuclear accumulation or overexpression of YAP was associated with poor prognosis for patients with ESCCs. 73 Another clinical study in ESCC 142 cases and 29 normal esophageal tissue cases found that the location of YAP in nuclear was much more in ESCC than in normal esophageal tissue. 74 Moreover, univariate analyses showed that enrichment of nuclear YAP was associated with tumor diameter, Ki67 expression, histological grade (1-2 versus 3), pathological T category (1 versus 2-4), and pathological TNM stage (stage 1 versus 2-4) in patients with ESCC, indicating that nuclear accumulation of YAP/TAZ is correlated with the patients' survival rate and prognosis. 74 Head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) is the most common of head and neck malignancy. Due to its anatomical location and the adjacent relationship, all aspects of tumor treatment are limited, which seriously affects the life quality of patients. 75 Evaluation of YAP expression by immunohistochemical tissue chip technology showed that YAP expression in HNSCC was significantly higher than in benign tissue and precancerous lesions and the poorer differentiation of tumor was along with the higher of YAP expression. 75 A recent study found that an ACTL6A/P63 complex suppressed WWC1 to activate YAP/TAZ and promote tumorigenesis in HNSCC. It was also observed that ACTL6A and an activated YAP/TAZ pathway conferred poor prognosis in primary HNSCC. 76 An experiment by Wang et al showed that the level of nuclear YAP/TAZ in fibroblasts associated with perineural invasion was higher than those in the stroma of normal mucosa, suggesting that the transcription programs mediated by YAP/TAZ in the fibroblasts may contribute to perineural invasion in HNSCC. 77 Interestingly, a recent study reported that upregulation of a circular RNA, circPVT1 together with TP53 mutation resulted in increased proliferation of HNSCC cell lines through the formation of mut-p53/YAP/TEAD complex. 78 
Oral squamous cell carcinoma
Genomic analysis showed that YAP/TAZ was amplified and overexpressed in oral squamous cell carcinoma (OSCC). 79 Hiemer et al demonstrated that nuclear accumulation of YAP/TAZ promoted OSCC cell proliferation, survival, and migration in vitro and was required for the growth and metastasis of OSCCin vivo. 80 Recent research showed the expression level of YAP was higher in OSCC tissues than that in adjacent normal tissues and YAP could drive the transcription of bcl-2 and c-myc genes subsequently leading to OSCC cell proliferation and resistance to apoptosis. 81 The expression of TAZ was significantly higher in tongue oral squamous cell carcinoma (TSCC) cells and specimens than those in non-cancerous cells and normal tongue mucosa. 82 Increase of TAZ expression inTSCC was significantly associated with tumor size, pathological grade, clinical stage, Ki-67 expression, reduced overall, and disease-free survival. 82 
Cervical squamous cell carcinoma
Cervical cancer is one of the most common malignancies in the female reproductive system. It is well known that the most common histological type of cervical cancer is squamous cell carcinoma, and its onset is a continuous developmental process from cervical squamous intraepithelial neoplasia to invasive cancer. 83 Liu et al reported that compared to normal tissues, YAP significantly increased in cervical SCC and was positively correlated with tumor differentiation, lymph node metastasis, and early recurrence. 84 Therapeutic potential on targeting YAP/TAZ in squamous cell carcinoma
Based on the above-mentioned studies, it is clear that the YAP/TAZ, which was expressed highly in SCCs, 68, 73, 75, 80, 84 has an oncogenic function. Therefore, a strategy against YAP/TAZ can prevent or at least slow the progression of SCCs. Fortunately, some inhibitors have been reported to be effective in treating SCC through direct and indirect inhibition of YAP/TAZ activation. An experimental evidence has demonstrated that verteporfin, an FDA-approved photodynamic therapy, inhibited YAP--EAD interaction and suppressed YAP-induced cancer cells overgrowth in vivo or in vitro. 85, 86 In addition, a report showed verteporfin also activated the Hippo pathway and sequestered YAP in the cytoplasm by upregulating 14-3-3σ. 87 A number of pathways have been identified to drive YAP/TAZ activities. Some can be used as a target to treat YAP-dependent cancer, such as Gprotein-coupled receptor (GPCRs). 88 It was reported that viral GPCR inhibited the Hippo pathway kinases Lats1/2 through Gq/11 and G12/13, which resulted in the activation of YAP/TAZ. 89 Targeting the downstream genes of YAP/ TAZ such as CYR61 and CTGF is also a strategy for SCC treatment, which is required for YAP/TAZ-dependent cancer progression.
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Conclusion and future perspectives
The Hippo pathway is pivotal in mammalian development and organ size control. YAP and TAZ are transcriptional coactivators that are negatively regulated by the Hippo pathway. YAP/TAZ activation promotes tumor formation and progression. A subsequent study reported that YAP/TAZ was overexpressed in a significant number of human cancers, especially in SCCs derived from different organs. Therefore, targeting the inhibition of YAP/TAZ activation would be an effective approach to treat YAP/TAZ-driven cancers. There are several strategies to directly target YAP/TAZ-TEAD, including targeting upstream signaling molecules and downstream YAP/TAZ target genes. However, the side effects of these treatments remain unclear. Moreover, there are no studies indicating that YAP/TAZ inhibition can prevent the growth of metastatic cancers.
